Think We Know What Predicts Weight Regain? Think Again Think We Know What Predicts Weight Regain? Think Again

Sedentary time, eating fast food, and weighing oneself less than weekly were associated with weight regain after Roux-en-Y gastric bypass surgery, a large study has found.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

ConclusionsAt similar WL, AGB lost more LM and VAT than MWL; RYGB similarly lost more VAT. Given the metabolic benefits of reducing VAT and retaining LM, larger studies should confirm the changes in BC after surgical versus medical WL.Clinical Trial RegistrationNCTDK089557 –ClinicalTrials.gov
Source: Obesity Surgery - Category: Surgery Source Type: research
Alyce M. Martin1, Emily W. Sun1, Geraint B. Rogers2,3 and Damien J. Keating1,4* 1Molecular and Cellular Physiology Laboratory, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia 2Microbiome Research Laboratory, Flinders University, Adelaide, SA, Australia 3Infection and Immunity, South Australian Health and Medical Research Institute, Adelaide, SA, Australia 4Nutrition and Metabolism, South Australian Health and Medical Research Institute, Adelaide, SA, Australia The microbial community of the gut conveys significant benefits to host physiology. A clear relationship has now bee...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Bariatric surgery is an effective and therapeutic way for different metabolic diseases. It has become a focus of attention about the effects and molecular mechanisms to bone metabolism.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Original articles Source Type: research
Conclusions: Bariatric surgery appears to be capable of partially reversing the obesity-related epigenome. The identification of potential epigenetic biomarkers predictive for the success of bariatric surgery may open new doors to personalized therapy for severe obesity. Introduction Obesity is currently a huge healthcare problem, worldwide, and is a risk factor for several diseases such as type 2 diabetes (T2D), cardiovascular disease and cancer (1). As the prevalence of obesity reaches pandemic proportions, this metabolic disease is estimated to become the biggest cause of mortality in the near future (2). In fact,...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
ConclusionsA baseline low NLR is associated with long-term T2D remission in obese patients undergoing metabolic surgery, suggesting that circulating inflammatory cells (i.e., neutrophils) might negatively impact on T2D remission.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
ConclusionThis is the first report from the MENA region on the long-term outcomes of RYGB in the treatment of type II DM. The results are similar to those in the international literature.
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
This study is a nationwide cohort study using Swedish registers, with basically no patients lost to follow-up during up to 7 years after surgery. Methods: The effect of RYGB on type 2 diabetes drug treatment was evaluated in this nationwide matched cohort study. Participants were 22,047 adults with BMI ≥30 identified in the nationwide Scandinavian Surgical Obesity Registry, who underwent primary RYGB between 2007 and 2012. For each individual, up to 10 general population comparators were matched on birth year, sex, and place of residence. Prescription data were retrieved from the nationwide Swedish Prescribed Drug Re...
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research
Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist. Introduction Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone with anorexigenic properties (1). The GLP-1 receptor agonist (GLP-1RA) liraglutide is known to induce weight loss in patients with type 2 diabetes as well as in patients with type 1 diabetes (2–5). However, the exact me...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusion Human microbiome is normal flora for humans, which has been proved to be of symbiotic relationship with humans and harmless to humans. If the microbes that breed in the human body become “unhealthy,” it will definitely affect the host's physical condition. People are continuing to explore the pathologic relationship between microorganisms and the human body through high-throughput sequencing technologies and analysis systems. However, it is a pity that their pathogenesis cannot be fully understood as yet. Considering that relying only on conventional experimental methods is time-consuming an...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Two modifications of Roux ‐en‐Y gastric bypass (RYGB), one anastomosis gastric bypass (OAGB) and Roux‐en‐Y banded gastric bypass (BGBP), are gaining popularity in use because the OAGB is reported to be a simpler operation, and the BGBP is reported to have sustained weight loss compared to standard RYGB. A retrospecti ve review and analysis of data comparing outcomes up to 5 years after BGBP and OAGB from a prospectively maintained database of all bariatric metabolic operations in 2012 was performed. Eighty‐two patients underwent a BGBP and 90 an OAGB. The average age and body mass index were 44.12 and 43.97 an d ...
Source: Clinical Obesity - Category: Eating Disorders & Weight Management Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
More News: Diabetes | Endocrinology | Gastric Bypass | Gastroenterology | Health | Study